Transaction Overview
Shanghai Henlius Biotech, Inc. (Stock code: 2696.HK) successfully listed on the Hong Kong Stock Exchange on September 25, 2019. CMBI acted as Joint Sponsor, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager for this IPO.
Henlius is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative drugs for patients worldwide. Since inception in 2010, Henlius has established, and continue to expand, a comprehensive product pipeline of both biosimilars and bio-innovative drugs. As at the Latest Practicable Date, in addition to the biosimilar product the Company had commercially launched, namely HLX01 (汉利康), Henlius had developed in-house over 20 biologic drug candidates and several immuno-oncology combination therapies in pipeline, including (i) two mAb candidates with NDA accepted by the NMPA, including one mAb candidate with MAA accepted by the EMA, (ii) two mAb candidates undergoing Phase 3 clinical trials and six mAb candidates undergoing Phase 1/2 clinical trials, and two immuno-oncology combination therapies undergoing Phase 3 clinical trials and (iii) 31 IND approvals received across different jurisdictions.
Henlius issued 64,695,400 shares (assuming the Over-allotment Option is not exercised). The offering price was set at HK$ 49.60, and the offering amount was approximately HK$ 3,208.9 million (assuming the Over-allotment Option is not exercised). The offering has been widely recognized by international and domestic investors, and over-subscribed in International Offering. The investment from cornerstone investors, including Cayman Henlius, AI-Rayyan Holding LLC (a wholly-owned subsidiary of Qatar Investment Authority), AVICT Global Holdings Limited(under effective control of Shenzhen Putai Investment Development Limited) and Zhejiang Staidson Investment Co., Ltd., represented approximately 34.19% of the total offer size.
Acting as the Joint Sponsor, CMBI has played an important role in the deal such as deal execution and regulatory communications. Leveraging the advantages for Chinese investors and high net worth customers, CMBI made positive contributions in investor introduction and marketing, laying a solid foundation for the successful listing of Henlius.
Source: Company Announcement
About Henlius
Henlius is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative drugs for patients worldwide. Henlius is the first biopharmaceutical company to receive NDA approval from the NMPA for a monoclonal antibody biosimilar in accordance with the Biosimilar Guidelines, the prevailing PRC regulation on biosimilar evaluation and marketing approval, and the first to commercially launch a biosimilar product in China.
Since inception in 2010, Henlius has established, and continue to expand, a comprehensive product pipeline of both biosimilars and bio-innovative drugs. As at the Latest Practicable Date, in addition to the biosimilar product the Company had commercially launched, namely HLX01 (汉利康), Henlius had developed in-house over 20 biologic drug candidates and several immuno-oncology combination therapies in pipeline, including (i) two mAb candidates with NDA accepted by the NMPA, including one mAb candidate with MAA accepted by the EMA, (ii) two mAb candidates undergoing Phase 3 clinical trials and six mAb candidates undergoing Phase 1/2 clinical trials, and two immuno-oncology combination therapies undergoing Phase 3 clinical trials and (iii) 31 IND approvals received across different jurisdictions.
HLX01 (汉利康) received NDA approval for commercialisation from the NMPA on 22 February 2019 for the non-Hodgkin lymphoma indication, becoming the first biosimilar drug approved and commercially launched in China in accordance with the Biosimilar Guidelines. The first prescription of HLX01 (汉利康) was issued on 16 May 2019. As at 30 June 2019, Henlius had delivered 20,638 vials of HLX01 (汉利康).
Source: Prospectus
